{
    "root": "301f35b4-d8ad-4a57-e063-6294a90af655",
    "code": "34391-3",
    "codeSystem": "2.16.840.1.113883.6.1",
    "displayName": "HUMAN PRESCRIPTION DRUG LABEL",
    "name": "levofloxacin",
    "value": "20250312",
    "ingredients": [
        {
            "name": "MAGNESIUM STEARATE",
            "code": "70097M6I30"
        },
        {
            "name": "CELLULOSE, MICROCRYSTALLINE",
            "code": "OP1R32D61U"
        },
        {
            "name": "POLYETHYLENE GLYCOL 6000",
            "code": "30IQX730WE"
        },
        {
            "name": "TALC",
            "code": "7SEV7J4R1U"
        },
        {
            "name": "TITANIUM DIOXIDE",
            "code": "15FIX9V2JP"
        },
        {
            "name": "CROSPOVIDONE",
            "code": "2S7830E561"
        },
        {
            "name": "LEVOFLOXACIN",
            "code": "6GNT3Y5LMF"
        },
        {
            "name": "HYPROMELLOSES",
            "code": "3NXW29V3WO"
        }
    ],
    "indications": "Levofloxacin is a fluoroquinolone antibacterial indicated in adults (18 years of age and older) with infections caused by designated, susceptible bacteria and in pediatric patients where indicated ( 1 , 12.4 ). Pneumonia: Nosocomial ( 1.1 ) and Community Acquired ( 1.2 , 1.3 ) Skin and Skin Structure Infections (SSSI): Complicated ( 1.4 ) and Uncomplicated ( 1.5 ) Chronic bacterial prostatitis ( 1.6 ) Inhalational Anthrax, Post-Exposure in adult and pediatric patients ( 1.7 ) Plague in adult and pediatric patients ( 1.8 ) Urinary Tract Infections (UTI): Complicated ( 1.9 , 1.10 ) and Uncomplicated ( 1.12 ) Acute Pyelonephritis ( 1.11 ) Acute Bacterial Exacerbation of Chronic Bronchitis ( 1.13 ) Acute Bacterial Sinusitis ( 1.14 ) Usage To reduce the development of drug-resistant bacteria and maintain the effectiveness of levofloxacin and other antibacterial drugs, levofloxacin should be used only to treat or prevent infections that are proven or strongly suspected to be caused by bacteria ( 1.15 ).",
    "contraindications": "Administer levofloxacin tablets to pediatric patients weighing 30 kg and greater only ( 2.1 , 2.2 ). Levofloxacin tablets cannot be administered to pediatric patients who weigh less than 30 kg because of the limitations of the available strengths. Alternative formulations of levofloxacin may be considered for pediatric patients who weigh less than 30 kg ( 2.2 ). Dosage in Adult and Pediatric Patients with Creatinine Clearance greater than or equal to 50 mL/minute ( 2.1 , 2.2 ) Type of Infection Dose Every 24 hours Duration (days) Nosocomial Pneumonia ( 1.1 ) 750 mg 7 to 14 Community Acquired Pneumonia ( 1.2 ) 500 mg 7 to 14 Community Acquired Pneumonia ( 1.3 ) 750 mg 5 Complicated SSSI ( 1.4 ) 750 mg 7 to 14 Uncomplicated SSSI ( 1.5 ) 500 mg 7 to 10 Chronic Bacterial Prostatitis ( 1.6 ) 500 mg 28 Inhalational Anthrax (Post-Exposure) ( 1.7 ) Adults and Pediatric Patients 50 kg or greater 500 mg 60 Pediatric Patients 30 kg to less than 50 kg (2.2) 250 mg every 12 hours 60 Plague ( 1.8 ) Adults and Pediatric Patients 50 kg or greater 500 mg 10 to 14 Pediatric Patients 30 kg to less than 50 kg (2.2) 250 mg every 12 hours 10 to 14 Complicated UTI ( 1.9 ) or Acute Pyelonephritis ( 1.11 ) 750 mg 5 Complicated UTI ( 1.10 ) or Acute Pyelonephritis ( 1.11 ) 250 mg 10 Uncomplicated UTI ( 1.12 ) 250 mg 3 Acute Bacterial Exacerbation of Chronic Bronchitis ( 1.13 ) 500 mg 7 Acute Bacterial Sinusitis ( 1.14 ) 750 mg 5 500 mg 10 to 14 Adjust dose for creatinine clearance less than 50 mL/minute ( 2.3 , 8.6 , 12.3 )",
    "warningsAndPrecautions": "Levofloxacin Tablets USP, 250 mg are white to off white, modified capsule-shaped, biconvex, film-coated tablets debossed with logo of 'ZC55' on one side and plain on other side and are supplied as follows:\n                  NDC 72578-098-18 in bottles of 50 tablets with child-resistant closures\n                  NDC 72578-098-01 in bottles of 100 tablets with child-resistant closures\n                  NDC 72578-098-05 in bottles of 500 tablets\n                  Levofloxacin Tablets USP, 500 mg are white to off white, modified capsule-shaped, biconvex, film-coated tablets debossed with logo of 'ZC56' on one side and plain on other side and are supplied as follows:\n                  NDC 72578-099-18 in bottles of 50 tablets with child-resistant closures\n                  NDC 72578-099-01 in bottles of 100 tablets with child-resistant closures\n                  NDC 72578-099-05 in bottles of 500 tablets\n                  NDC 72578-099-10 in bottles of 1,000 tablets\n                  Levofloxacin Tablets USP, 750 mg are white to off white, modified capsule-shaped, biconvex, film-coated tablets debossed with logo of 'ZC57' on one side and plain on other side and are supplied as follows:\n                  NDC 72578-100-92 in bottles of 20 tablets with child-resistant closures\n                  NDC 72578-100-06 in bottles of 30 tablets with child-resistant closures\n                  NDC 72578-100-18 in bottles of 50 tablets with child-resistant closures\n                  NDC 72578-100-01 in bottles of 100 tablets with child-resistant closures\n                  NDC 72578-100-05 in bottles of 500 tablets\n                  \n                     Storage\n                  \n                  Store at 20째C to 25째 C (68째F to 77째 F) [see USP Controlled Room Temperature]. Dispense in a well closed container as described in the USP.",
    "adverseReactions": "Known hypersensitivity to levofloxacin or other quinolones ( 4 , 5.7 )"
}